Alector, Inc. (ALEC) is a leading clinical-stage biopharmaceutical firm focused on creating breakthrough therapies for neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. The company harnesses its innovative immuno-neurology platform to engage the immune system in revitalizing neuronal health and function. Headquartered in South San Francisco, Alector is committed to advancing the treatment landscape within neurology, showcased by a robust pipeline of differentiated product candidates that hold the potential to significantly alter the course of these challenging conditions.